📣 VC round data is live. Check it out!
- Public Comps
- GIMV
GIMV Valuation Multiples
Discover GIMV's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like FIBRA Macquarie, L1 Long Short Fund, HBM Healthcare Investments, Antin Infrastructure Partners and more.
GIMV Overview
About GIMV
GIMV NV is a Belgium-based company active in investing in companies having growth potential, with the objective of supporting its growth into market leaders. The company invests with a focus on four platforms, which are also its segments: Consumer, Health and Care, Smart Industries, and Sustainable Cities. Its geographical segments include Belgium, Netherlands, Germany, France, and the Rest of Europe and Other countries.
Founded
1980
HQ

Employees
94
Website
Sectors
Financials (FY)
EV
$2B
Valuation Multiples
Start free trialGIMV Financials
GIMV reported last fiscal year revenue of $393M.
In the same fiscal year, GIMV generated $255M in net income.
GIMV P&L
In the most recent fiscal year, GIMV reported revenue of $393M and net income of $255M.
GIMV is profitable as of last fiscal year, with net margin of 65%.
Financial data powered by Morningstar, Inc.
GIMV Stock Performance
GIMV has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
GIMV's stock price is $53.58.
GIMV share price decreased by 5.4% in the last 30 days, and increased by 11.1% in the last year.
GIMV has an EPS (earnings per share) of $6.94.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -5.3% | -5.4% | 0.5% | 11.1% | $6.94 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGIMV Valuation Multiples
GIMV trades at 6.1x EV/Revenue multiple.
GIMV Financial Valuation Multiples
As of June 3, 2026, GIMV has market cap of $2B and EV of $2B.
GIMV has a P/E ratio of 7.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified GIMV Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


GIMV Margins & Growth Rates
In the most recent fiscal year, GIMV reported net margin of 65%.
GIMV Margins
GIMV Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
GIMV Operational KPIs
GIMV's revenue per employee in the last FY averaged $4.2M, while opex per employee averaged $1.5M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
GIMV Competitors
GIMV competitors include FIBRA Macquarie, L1 Long Short Fund, HBM Healthcare Investments, Antin Infrastructure Partners, L1 Group, AFP ProVida, Tri-Continental, Patria Investments, BWP Gr and AG Anadolu Grubu Holding.
Most GIMV public comparables operate across PE & VC and Asset Management.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 10.5x | 10.4x | 13.8x | 13.6x | |||
| 9.7x | - | - | - | |||
| 6.1x | 20.7x | - | - | |||
| 4.8x | 4.8x | 8.3x | 8.8x | |||
| 18.0x | 5.6x | 77.1x | 7.8x | |||
| 4.8x | - | 7.4x | - | |||
| 7.5x | - | - | - | |||
| 5.1x | 5.0x | 10.1x | 9.3x | |||
This data is available for Pro users. Sign up to see all GIMV competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by GIMV
GIMV has acquired 29 companies to date.
Last acquisition by GIMV was on July 22nd 2025. GIMV acquired Hemink Groep for undisclosed valuation.
Latest Acquisitions by GIMV
| Description | Hemink Groep is a Dutch property service provider headquartered in Deventer delivering maintenance, renovation, and complete outfitting for residential and commercial buildings. The company handles electrical installations, HVAC systems, plumbing, and painting projects across the Netherlands. With a workforce specialized in multi-trade execution, Hemink Groep manages turnkey projects from initial assessment to final handover. Serving housing associations, property developers, and corporate clients, the firm emphasizes sustainable building practices and compliance with Dutch building codes. | Alpine Hearing Protection is a Netherlands-based manufacturer of custom-fit earplugs for musicians, motorsport enthusiasts, and industrial workers. Its product line includes models like MusicSafe, MotoSafe, and WorkSafe, sold through retailers in Europe and beyond. | The Spice Factory is a U.S.-based manufacturer and wholesaler of bulk herbs, spices, seasonings, and custom blends for foodservice, retail, and industrial clients. Operating from Ohio, it sources organic and conventional products including pepper, garlic, paprika, and spice mixes, offering private labeling, grinding, and packaging services compliant with FDA standards. | Tibbloc is a France-based provider of rental services for temporary heating, cooling, air treatment, steam generation, and compressed air equipment for construction and industrial projects. | |
| HQ Country | |||||
| HQ City | Enschede | Utrecht | Braine-l'Alleud | Nantes | |
| Deal Date | 22 Jul 2025 | 24 Jun 2025 | 20 Feb 2025 | 4 Dec 2024 | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all GIMV acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by GIMV
GIMV has invested in 39 companies to date.
Latest investment by GIMV was on January 20th 2026. GIMV invested in Exciva in their $60M Series B round (EV/Revenue multiple available to Pro users).
Latest Investments by GIMV
| Description | Exciva is a Heidelberg-based provider of targeted drug rescue programs for pharmaceutical research and development. The company develops symptomatic and disease-modifying treatments by repurposing approved drugs for new indications, including therapies, cures, prophylactics, supplements, and formulations. These efforts support healthcare organizations in rescuing and reusing existing drugs through specialized methods of production and application. | Kinaset Therapeutics is a Melbourne-headquartered clinical-stage company developing inhaled therapeutics for respiratory diseases. Its lead asset KIN-301 targets idiopathic pulmonary fibrosis with Phase 1 data showing safety in 50 patients. The pipeline includes candidates for COPD and asthma, licensed from Monash University research. | spineart designs and distributes sterile-packed implants with barcoded traceability and compact instrument sets from its Swiss operations. The portfolio covers minimally invasive surgery, motion preservation, fusion, biologics, and fracture treatments validated clinically for spine surgeons in Europe, Asia, and the Americas. | Kivu Bioscience is a biopharmaceutical company developing antibody-drug conjugates for oncology and immunology. Headquartered in Basel, Switzerland, it engineers site-specific ADCs with proprietary linkers and payloads for improved therapeutic indices. Kivu advances candidates like KV-001 targeting solid tumors through preclinical stages, leveraging platforms from former Roche scientists for scalable manufacturing. | |
| HQ Country | |||||
| HQ City | Heidelberg | Boston, MA | Geneva | San Francisco, CA | |
| Deal Date | 20 Jan 2026 | 10 Jan 2026 | 26 Sep 2025 | 28 Oct 2024 | |
| Round | Series B | Series B | Undisclosed stage | Series A | |
| Raised | $60M | $103M | $31M | $92M | |
| Investors | Andera Partners; Carma Fund; EQT; Fountain Healthcare Partners; GIMV; LBBW VC; LifeArc Ventures; Modi Ventures | 5AM Ventures; Atlas Venture; EQT; Forge Life Science Partners; GIMV; Pictet Alternative Advisors; RA Capital Management; Schroders Capital; Sixty Degree Capital; Vivo Capital; Willett Advisors LLC | EGS Beteiligungen; GIMV | BioGeneration Ventures; BOM; GIMV; HealthCap; M Ventures; Novo Holdings; Red Tree Venture Capital | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all GIMV investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout GIMV
| When was GIMV founded? | GIMV was founded in 1980. |
| Where is GIMV headquartered? | GIMV is headquartered in Belgium. |
| How many employees does GIMV have? | As of today, GIMV has over 94 employees. |
| Who is the CEO of GIMV? | GIMV's CEO is Koen Dejonckheere. |
| Is GIMV publicly listed? | Yes, GIMV is a public company listed on Euronext Brussels. |
| What is the stock symbol of GIMV? | GIMV trades under GIMB ticker. |
| When did GIMV go public? | GIMV went public in 1997. |
| Who are competitors of GIMV? | GIMV main competitors include FIBRA Macquarie, L1 Long Short Fund, HBM Healthcare Investments, Antin Infrastructure Partners, L1 Group, AFP ProVida, Tri-Continental, Patria Investments, BWP Gr, AG Anadolu Grubu Holding. |
| What is the current market cap of GIMV? | GIMV's current market cap is $2B. |
| What is the current revenue of GIMV? | GIMV's last fiscal year revenue is $393M. |
| What is the current EV/Revenue multiple of GIMV? | Current revenue multiple of GIMV is 6.1x. |
| Is GIMV profitable? | No, GIMV is not profitable. |
| How many companies GIMV has acquired to date? | As of June 2026, GIMV has acquired 29 companies. |
| What was the largest acquisition by GIMV? | $259M acquisition of Smart Battery Solutions on 28th May 2019 was the largest M&A GIMV has done to date. |
| In how many companies GIMV has invested to date? | As of June 2026, GIMV has invested in 39 companies. |
| What was the last GIMV investment? | On 20th January 2026 GIMV invested in Exciva, participating in a $60M Series B round, alongside Andera Partners, Carma Fund, EQT, Fountain Healthcare Partners, LBBW VC, LifeArc Ventures, and Modi Ventures. |
| In what companies GIMV invested in? | GIMV invested in Kinaset Therapeutics, JenaValve Technology, Kivu Bioscience, Precirix, Mediar Therapeutics, Complement Therapeutics, ImmunOs Therapeutics, Covagen, Exciva, Anjarium Biosciences, Almaviva Santé, ImCheck Therapeutics, Lampiris, FIRE1, Breath Therapeutics, SynOx Therapeutics, iSTAR Medical, Endosense, Biotalys, Biom'Up, and 19 other companies. |
See public comps similar to GIMV
Lists including GIMV
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.





